Survival Benefit of Traditional Chinese Herbal Medicine (A Herbal Formula for Invigorating Spleen) in Gastric Cancer Patients with Peritoneal Metastasis
Table 1
Patients and cancer baseline characteristics.
Characteristic
Treatment
value
TCHM ()
Non-TCHM ()
Sex (%)
Male
26 (55.3%)
34 (73.9%)
0.062
Age (%)
<60
29 (61.7%)
33 (71.7%)
0.310
≥60
18 (38.3%)
13 (28.3%)
Primary tumor site (%)
Gastroesophageal junction
2 (4.3%)
2 (4.3%)
0.983
Stomach
45 (95.7%)
44 (95.7%)
Histology (%)
Intestinal
30 (63.8%)
31 (67.4%)
0.973
Diffuse
3 (6.4%)
1 (2.2%)
Mixed
13 (27.7%)
12 (26.1%)
Missing
1 (2.1%)
2 (4.3%)
Number of metastatic sites (%)
1~2
32 (68.1%)
31 (67.4%)
0.944
>2
15 (31.9%)
15 (32.6%)
Chemotherapy
1~2 cycles
10 (21.3%)
16 (34.8%)
0.150
3 cycles and more
37 (78.7%)
30 (65.2%)
First-line chemotherapy scheme
Single-agent regimena
5 (10.6%)
2 (4.3%)
0.945
Joint regimen of 2 drugsb
17 (36.2%)
21 (45.7%)
Joint regimen of 3 drugsc
21 (44.7%)
21 (45.7%)
Other regimend
4 (8.5%)
2 (4.3%)
Intraperitoneal chemotherapy
Nonintraperitoneal chemotherapy
40 (85.1%)
43 (93.5%)
0.197
Intraperitoneal chemotherapy
7 (14.9%)
3 (6.5%)
Fluorouracil.
bFluorouracil plus cisplatin/oxaliplatin.
cFluorouracil plus cisplatin/oxaliplatin plus anthracycline or paclitaxel/docetaxel.
dFluorouracil plus others.
